Author(s): Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, Goodwin JW, Twardowski PW,
Abstract Share this page
Abstract STUDY TYPE: Prognosis (inception cohort). LEVEL OF EVIDENCE: 1b. OBJECTIVE: To evaluate the epidermal growth factor receptor (EGFR)-targeted agent ZD1839 in patients who failed one previous chemotherapeutic regimen for metastatic transitional cell carcinoma (TCC), and to correlate patterns of response with the expression of EGFR. PATIENTS AND METHODS: Thirty-one patients with metastatic TCC of the urothelial tract were treated with ZD1839 500 mg oral daily. Patients were required to have a pretreatment biopsy to assess EGF expression. RESULTS: The median progression-free survival was 2 months, with only two patients (6.5\%) surviving past 6 months with no disease progression. Thirty patients were evaluable for toxicity; there was grade 4 cerebrovascular ischaemia and an increase in creatinine level. All patients were evaluable for response, with one confirmed partial response (3\%; 95\% confidence interval, CI, 0-17\%) in a patient with pulmonary metastases. All patients have died, and the estimated median (95\% CI) survival is 3 (2-7) months. CONCLUSIONS: ZD1839 is ineffective as a second-line agent for urothelial carcinoma.
This article was published in BJU Int
and referenced in Journal of Cytology & Histology